Loading...

HEPION PHARMACEUTICALS INC Investor Conferences 8-K Filing

HPN

HEPION PHARMACEUTICALS INC

()

2023 8-K

Management Change

License Agreement

Management Change

Asset Acquisitions

Forced Delisting

Asset Acquisitions

Balance Sheet Update

Equity Financing

Financial Update

Clinical Trial Update

Nasdaq Compliance Notice

Management Changes

Merger Agreement

Appointment of Director

Management Changes

Registered Direct Offering ...

Resignation of Director

Dismissal of BDO USA, P.C. ...

Resignation of CEO and Rest...

Securities Purchase Agreement

Investor Meetings

Equity Offerings

Annual Meeting of Stockholders

Regulation FD Disclosure, O...

Reverse Stock Split

External Links:

Hepion Pharmaceuticals, Inc. plans to conduct meetings with third parties to present its corporate slide presentation, and announces positive topline results from its Phase 2 ALTITUDE-NASH clinical trial.

AI Assistant

HEPION PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.